Daly MB, Pal T, AlHilli H, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Accessed April 3, 2025. To view the most recent version, visit https://www.nccn.org

• PubMed
Daly MB, Pal T, AlHilli H, NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Accessed April 3, 2025. To view the most recent version, visit https://www.nccn.org)| false
• Search Google Scholar
• Export Citation

Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375:443–453.

• PubMed
Pritchard CC, Mateo J, Walsh MF, Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375:443–453.)| false
• Search Google Scholar
• Export Citation

Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 2019;5:523–528.

• PubMed
Nicolosi P, Ledet E, Yang S, Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 2019;5:523–528.)| false
• Search Google Scholar
• Export Citation

Page EC, Bancroft EK, Brook MN, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 2019;76:831–842.

• PubMed
Page EC, Bancroft EK, Brook MN, Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 2019;76:831–842.)| false
• Search Google Scholar
• Export Citation

Bancroft EK, Page EC, Brook MN, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol 2021;22:1618–1631.

• PubMed
Bancroft EK, Page EC, Brook MN, A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol 2021;22:1618–1631.)| false
• Search Google Scholar
• Export Citation

Cheng HH, Follmer K, de la Calle CM, et al. Prostate screening for men with inherited risk of developing aggressive prostate cancer: the PATROL study. Presented at the 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract TPS357.

• PubMed
Cheng HH, Follmer K, de la Calle CM, Prostate screening for men with inherited risk of developing aggressive prostate cancer: the PATROL study. Presented at the 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract TPS357.)| false
• Search Google Scholar
• Export Citation

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.

• PubMed
Marabelle A, Le DT, Ascierto PA, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.)| false
• Search Google Scholar
• Export Citation

Gupta S, Weiss JM, Axell L, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. Accessed April 5, 2025. To view the most recent version, visit https://www.nccn.org

• PubMed
Gupta S, Weiss JM, Axell L, NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. Accessed April 5, 2025. To view the most recent version, visit https://www.nccn.org)| false
• Search Google Scholar
• Export Citation

León-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020;250:312–322.

• PubMed
León-Castillo A, Gilvazquez E, Nout R, Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020;250:312–322.)| false
• Search Google Scholar
• Export Citation

Wright JD, Silver ER, Tan SX, et al. Cost-effectiveness analysis of genotype-specific surveillance and preventive strategies for gynecologic cancers among women with Lynch syndrome. JAMA Netw Open 2021;4:e2123616.

• PubMed
Wright JD, Silver ER, Tan SX, Cost-effectiveness analysis of genotype-specific surveillance and preventive strategies for gynecologic cancers among women with Lynch syndrome. JAMA Netw Open 2021;4:e2123616.)| false
• Search Google Scholar
• Export Citation

Fillman C, Anantharajah A, Marmelstein B, et al. Combining clinical and molecular characterization of CDH1: a multidisciplinary approach to reclassification of a splicing variant. Fam Cancer 2023;22:521–526.

• PubMed
Fillman C, Anantharajah A, Marmelstein B, Combining clinical and molecular characterization of CDH1: a multidisciplinary approach to reclassification of a splicing variant. Fam Cancer 2023;22:521–526.)| false
• Search Google Scholar
• Export Citation

Xicola RM, Li S, Rodriguez N, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 2019;56:838–843.

• PubMed
Xicola RM, Li S, Rodriguez N, Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 2019;56:838–843.)| false
• Search Google Scholar
• Export Citation

Roberts ME, Ranola JMO, Marshall ML, et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol 2019;5:1325–1331.

• PubMed
Roberts ME, Ranola JMO, Marshall ML, Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol 2019;5:1325–1331.)| false
• Search Google Scholar
• Export Citation

Ryan CE, Fasaye GA, Gallanis AF, et al. Germline CDH1 variants and lifetime cancer risk. JAMA 2024;332:722–729.

• PubMed
Ryan CE, Fasaye GA, Gallanis AF, Germline CDH1 variants and lifetime cancer risk. JAMA 2024;332:722–729.)| false
• Search Google Scholar
• Export Citation

Mi EZ, Mi EZ, di Pietro M, et al. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest Endosc 2018;87:408–418.

• PubMed
Mi EZ, Mi EZ, di Pietro M, Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest Endosc 2018;87:408–418.)| false
• Search Google Scholar
• Export Citation

Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020;21:e386397.

• PubMed
Blair VR, McLeod M, Carneiro F, Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020;21:e386397.)| false
• Search Google Scholar
• Export Citation